Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide
1997

Study of Topotecan and Etoposide for Cancer Treatment

Sample size: 30 publication Evidence: moderate

Author Information

Author(s): VMM Herben, WW ten Bokkel Huinink, AC Dubbelman, IAM Mandjes, Y Groot, DM van Gortel-van Zomeren, JH Beijnen

Primary Institution: Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute

Hypothesis

To determine the maximum tolerated dose and dose-limiting toxicities of topotecan in combination with etoposide.

Conclusion

The combination of topotecan and etoposide resulted in significant neutropenia as the main dose-limiting toxicity.

Supporting Evidence

  • Neutropenia was the principal dose-limiting toxicity observed.
  • 64% of patients had stable disease for at least 4 months.
  • A partial response was observed in a patient with metastatic ovarian carcinoma.
  • Patients received topotecan and etoposide in a sequential regimen.

Takeaway

Doctors tested a new cancer treatment using two drugs, topotecan and etoposide, and found that it could make patients' blood counts drop too low, which is a problem.

Methodology

Patients with advanced solid tumors received topotecan intravenously followed by oral etoposide, with dose levels escalated to find the maximum tolerated dose.

Limitations

The study was limited by the high incidence of neutropenia and the inability to escalate doses due to bone marrow recovery issues.

Participant Demographics

30 patients, 11 men and 19 women, median age 54 years.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication